Beneficial effect of Raloxifene on high turn-over bone in chronic hemodialysis patients

Beneficial effect of Raloxifene on high turn-over bone in chronic hemodialysis patients - Effect of Raloxifene on high turn-over bone in dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001911

Enrollment

Registered

2009-05-01

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease postmenopausal osteoporosis

Interventions

medication of Raloxifene

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal hemodialysis patients of 50 years old or over with high serum alkaline phosphatase levels (>= 370 U/L), BAP levels (>= 35.4 U/L), or TRAP-5b levels (>= 4.2 U/L).

Exclusion criteria

Exclusion criteria: 1. Patients prescribed with bisphosphonate, aluminium, lanthanum, cinacalcet. 2. Patients with venous thrombosis or its history. 3. Immobilised patients in long term. 4. Patients with anti-phospholipid antibody syndrome. 5. Patients in pregnancy (including its possibility) and lactation. 6. Patinets with history of allergy to Raloxifene. 7. Patients with liver dysfunction.

Design outcomes

Primary

Measure	Time frame
serum bone alkaline phosphatase (BAP) level serum bone-specific tartrate-resistant acid phosphatase (TRAP5b) level	—

Secondary

Measure	Time frame
serum levels od iPTH, calcium, phosphate, total cholesterol, and triacylglyceride	—

Countries

Japan

Contacts

Public ContactKatsuyuki Nagatoya

Osaka Medical College Blood Purification Center

katsuyuki@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026